We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
+2.11%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.4M
AUM Growth
+$8.29M
(+14%)
Cap. Flow
+$122M
Cap. Flow
% of AUM
183.83%
Top 10 Holdings %
Top 10 Hldgs %
32.21%
Holding
297
New
108
Increased
49
Reduced
51
Closed
72
Top Buys
| 1 |
Incyte
INCY
|
+$3.53M |
| 2 |
Teva Pharmaceuticals
TEVA
|
+$2.94M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$2.18M |
| 4 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$1.54M |
| 5 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
+$1.37M |
Top Sells
| 1 |
General Mills
GIS
|
+$2.52M |
| 2 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$2.31M |
| 3 |
Amgen
AMGN
|
+$2.08M |
| 4 |
Abbott
ABT
|
+$1.72M |
| 5 |
CLVS
Clovis Oncology, Inc.
CLVS
|
+$1.56M |
Sector Composition
| 1 | Healthcare | 41.81% |
| 2 | Consumer Discretionary | 7.1% |
| 3 | Consumer Staples | 6.25% |
| 4 | Communication Services | 0.99% |
| 5 | Materials | 0.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SAGE
51
PUT
DELISTED
Sage Therapeutics
SAGE
| $374K | 0.56% |
57,200
-16,800
| -23% | -$1.32M |
|
|
ICPT
52
PUT
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $336K | 0.51% |
+24,800
| New | +$2.67M |
|
53
Clorox
CLX
$11.6B
| $317K | 0.48% |
2,400
-7,223
| -75% | -$971K |
|
54
PTC Therapeutics
PTCT
$6.52B
| $287K | 0.43% |
+14,323
| New | +$280K |
|
|
DERM
55
CALL
DELISTED
Dermira, Inc.
DERM
| $282K | 0.43% |
+101,700
| New | +$2.66M |
|
|
56
General Mills
GIS
$20.3B
| $259K | 0.39% |
5,000
-45,896
| -90% | -$2.52M |
|
|
57
CALL
Incyte
INCY
$23.4B
| $249K | 0.38% |
43,700
+13,000
| +42% | +$1.64M |
|
|
AERI
58
DELISTED
Aerie Pharmaceuticals
AERI
| $246K | 0.37% |
5,060
+685
| +16% | +$37.4K |
|
59
CALL
Intuitive Surgical
ISRG
$122B
| $237K | 0.36% |
27,000
+13,500
| +100% | +$1.47M |
|
|
ARAV
60
DELISTED
Aravive, Inc. Common Stock
ARAV
| $224K | 0.34% |
+15,240
| New | +$1.54M |
|
61
PUT
Kimberly-Clark
KMB
$36B
| $214K | 0.32% |
18,900
+2,000
| +12% | +$244K |
|
|
LUMO
62
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $212K | 0.32% |
+2,311
| New | +$177K |
|
63
PUT
Vertex Pharmaceuticals
VRTX
$123B
| $209K | 0.32% |
46,200
+6,500
| +16% | +$978K |
|
64
uniQure
QURE
$2.77B
| $207K | 0.31% |
21,597
-20,337
| -48% | -$164K |
|
|
TSRO
65
CALL
DELISTED
TESARO, Inc.
TSRO
| $207K | 0.31% |
26,800
+6,000
| +29% | +$745K |
|
|
TWX
66
CALL
DELISTED
Time Warner Inc
TWX
| $195K | 0.29% |
75,800
+21,600
| +40% | +$2.19M |
|
|
AVXS
67
CALL
DELISTED
AveXis, Inc. Common Stock
AVXS
| $193K | 0.29% |
28,000
+7,000
| +33% | +$631K |
|
|
DBVT
68
CALL
DBV Technologies
DBVT
$870M
| $185K | 0.28% |
+8,470
| New | +$3.63M |
|
|
SAGE
69
DELISTED
Sage Therapeutics
SAGE
| $184K | 0.28% |
2,957
-6,873
| -70% | -$540K |
|
|
BLUE
70
CALL
DELISTED
bluebird bio
BLUE
| $176K | 0.27% |
+772
| New | +$1.08M |
|
71
CALL
Illumina
ILMN
$28.2B
| $175K | 0.26% |
7,299
| – | – |
|
|
K
72
DELISTED
Kellanova
K
| $175K | 0.26% |
2,982
-16,165
| -84% | -$1.02M |
|
73
CALL
PayPal
PYPL
$49.9B
| $174K | 0.26% |
30,000
-10,000
| -25% | -$599K |
|
74
CALL
Puma Biotechnology
PBYI
$434M
| $169K | 0.25% |
13,700
-7,200
| -34% | -$670K |
|
|
ICPT
75
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $164K | 0.25% |
+66,000
| New | +$7.11M |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q3 2017 Portfolio in Review
As of Q3 2017, FT Options held 297 positions worth $66.4M, up 14% from $58.1M the previous quarter. Its ten largest holdings account for 32% of the portfolio.
FT Options deployed $122M of net new capital in Q3 2017, opening 108 new positions and adding to 49 existing holdings. Its largest new stake was Incyte: 27,887 shares worth $3.26M.
By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.
On the sell side, the largest reduction was General Mills, an estimated $2.52M trimmed.
- FT Options's largest Q3 2017 buy was Incyte: 27,887 shares worth $3.26M.
- FT Options added most to Sio Gene Therapies Inc. Common Stock in Q3 2017, an estimated $1.37M increase.
- FT Options's biggest Q3 2017 reduction was General Mills, cutting an estimated $2.52M.
- FT Options fully exited Portola Pharmaceuticals, Inc. in Q3 2017, selling an estimated $2.31M.
- FT Options's ten largest holdings make up 32% of its $66.4M portfolio in Q3 2017.
- FT Options opened 108 new positions and closed 72 in Q3 2017.
- FT Options's portfolio value rose 14% quarter-over-quarter to $66.4M.
Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.